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Protein aggregationRetinitis pigmentosa, causing progressive blindness, is genetically heterogeneous. RP10, due to a defect in
inosine monophosphate dehydrogenase 1 (IMPDH1), shows autosomal dominant inheritance. Recombinantly
expressed clinical mutants show unaltered kinetic behaviour. It is unclear why reportedly impaired DNA
binding is important and how it would explain negative dominance. An alternative view relates to the mutant
proteins' tendency to aggregate. Regarding negative dominance, a key question is whether the defective
protein can subvert the function of its normal counterpart in the same cell. Potentially, the homotetrameric
structure of IMPDH1 might offer a vehicle for such an effect. We have established a reliable protocol for
reproducible refolding of recombinantly expressed IMPDH1 in vitro. Clinical mutants R224P and D226N both
show impaired folding. For equimolar mixtures of normal andmutant enzymes, independent refolding would
predict activity regain midway between pure mutant and pure normal. Under various conditions regain is
close to the mutant ﬁgure, suggesting that, in hybrid tetramers, mutant subunits impose their faulty
conformation on normal partners. The observed molecular recruitment is a negative counterpart of the intra-
allelic complementation, also mediated via oligomeric structure and postulated many years ago by Fincham.
These ﬁndings appear potentially to account for the negative dominant inheritance. This interpretation must
be provisional at present, as the predominant transcript in retina is an alternatively spliced version not fully
identical to that used in our study. The results nevertheless have a general signiﬁcance in pointing to a
mechanism for negative dominance that could be widespread.+353 1 283 7211.
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Retinitis pigmentosa (RP), characterised by progressive loss of
vision and ultimately total blindness, is genetically heterogeneous,
being attributable to mutations in various genes affecting retinal
metabolismand function [1]. Themostwidespread RPmutations occur
in the rhodopsin gene, but other forms of the disease result from
mutations in different retinal proteins [1]. One of these is the enzyme
inosinemonophosphate dehydrogenase 1 (IMPDH1), catalysing a step
in GTP production, required not only for nucleic acid synthesis but also
for cell signalling. The gene encoding this enzyme has been identiﬁed
as the locus for mutations causing RP10, a form of the disease
characterised by autosomal dominant negative inheritance [2–4].
Recombinant expression of two of the human clinicalmutants resulted
in proteins with virtually identical speciﬁc activity and kinetic
parameters to those of the normal enzyme [5]. Moreover, knockout
mice with a total deletion of IMPDH1 are much less visually impairedthan animals bearing a copy of one of the clinical mutations [6]. This
has encouraged the view that RNA Interferencei may offer a viable
therapy [6] since it strongly suggests an actively deleterious effect of
the mutant gene product in vivo. This ‘gain of function’, as opposed to
haploinsufﬁciency, would then account for negative dominance [4].
This raises two questions: ﬁrst, what is the critical defect in
mutated IMPDH1 that causes disease? Second, can the mutated
protein overcome or subvert the contribution of normal IMPDH1
molecules in a heterozygote, and, if so, how? In relation to the ﬁrst
question, Aherne et al. [5] reported that the mutant enzymes were
prone to aggregation, which might cause problems not only through
depletion of IMPDH1 activity but also by physical disruption via
accumulation of insoluble protein. Hedstrom et al. [7,8] maintain
instead that the key altered property of the mutated enzyme is a
damaged ability to bind DNA and suggest that aggregation may be an
artefact resulting from His tagging. These authors do not explain the
physiological signiﬁcance of DNA binding by IMPDH1. Neither do they
attempt to explain the negative dominance.
In pursuit of the simpler aggregation hypothesis, we ﬁrst examine
the folding behaviour of normal IMPDH1 and the clinical mutants in
vitro (without His tags) and subsequently seek a basis for negative
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Fig. 1. SDS-PAGE of recombinant IMPDH1 expression and puriﬁcation. Lane 1.
Supernatant of the crude extract of induced BL21 cells containing IMPDH1 construct;
Lane 2. Pellet of the crude extract of the same cell lysate; 3. Puriﬁed IMPDH1 inclusion
bodies; 4. Puriﬁed soluble refolded IMPDH1.
Table 1
Dependence of refolding yield on protein concentration.
a. Refolding of inclusion bodies
Protein concentration (μg/ml) 25 50 100 200 400 600 800
Speciﬁc IMPDH activity of
refolded protein (IU/mg)
0.0028 0.0086 0.044 0.12 0.22 0.18 0.09
• In these experiments with solubilised inclusion bodies A280 of 1 was taken to
represent 1 mg/ml.
b. Refolding of puriﬁed wild-type IMPDH1 after denaturation
Protein concentration (μg/ml) 100 150 200 250
Speciﬁc activity of refolded IMPDH1 (IU/mg) 0.64 0.79 0.75 0.68
• Here, the protein concentration was obtained by assay with bicinchoninic acid.
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has a homotetrameric structure. Over 50 years ago, J.R.S. Fincham
[9,10] described ‘inter-allelic complementation’ in which a sexual
cross between two null mutants (in Neurospora crassa) resulted in
progenywith a positive phenotype. The explanation, he suggested, lay
in subunit interaction in an oligomeric protein structure: structurally
sound but catalytically impotent subunits, for example, in a hybrid
oligomer might provide a scaffold allowing expression of the activity
of differently defective subunits carrying the full set of catalytic
machinery but unable on their own to attain the correct folded
conformation. Turned around, this elegant concept could equally
explain negative dominance. If the faultily folded subunits impose
their shape or behaviour on their neighbours, the outcomewould be a
negative phenotype. More recently, prion proteins have offered a
striking example of such subversive recruitment through interaction
between protein subunits [11].
2. Materials and methods
2.1. Molecular genetics
The wild-type IMPDH1 cDNA in the pGEM vector was received
from Dr Beverly Mitchell, University of North Carolina at Chapel Hill,
USA. Primerswere designed to introduce anNde1 site at the 5′ end and
an Xho1 site at the 3′ end of the IMPDH1 cDNA sequence. The 1.5 kb
cDNA was ampliﬁed by PCR with Pfu DNA polymerase (Stratagene).
The single point mutations CGC to CCC (Arg224Pro) and GAC to AAC
(Asp226Asn) were introduced using the Quikchange site-directed
mutagenesis kit (Stratagene). For efﬁcient protein expression, IMPDH1
cDNA insertswere then cloned into theNde1 and Xho1 sites of the pET-
21a vector (Novagen), which ensures that no extraneous tags are
incorporated into the protein sequence. All inserts were sequenced
completely to verify the presence of mutations.
2.2. Cell growth and protein expression
BL21(DE3) cells containing the various constructs were grown at
37 °C in LB medium with 100 μg/ml ampicillin and induced for 5 h
with IPTG. Cell pellets were suspended in 100 mM Tris, pH 8.0,
100 mM KCl, 4 mM EDTA, 5 mM DTT with protease inhibitors, and
were broken by sonication. Inclusion bodies were collected by
centrifugation at 18,000 rpm at 4 °C for 30 min and washed 5 times
with the aforementioned buffer containing 2% Triton X-100.
2.3. Preparation of pure soluble enzyme from inclusion bodies
The washed inclusion bodies were dissolved in 50 mM Tris, pH 8.0
with 8 M Gdn-HCl and 5 mM DTT. Protein concentration was
estimated from A280. The proteins were refolded by dilution into Tris
buffer, pH 8.0, containing 400 mMarginine, 200 μMNAD+ and 10 mM
DTT. Enzyme activity was measured via formation of NADH at 340 nm
in the following reaction mixture: 100 mM Tris, pH 8.0, 400 μM IMP,
400 μM NAD+, 100 mM KCl, 4 mM EDTA. To purify refolded inclusion
bodies, (NH4)2SO4was added to 0.4 M and the samplewas loaded on a
Butyl Sepharose column pre-equilibrated with 50 mM Tris, pH 8.0,
100 mM KCl, 4 mM EDTA, 0.4 M (NH4)2SO4. Refolded IMPDH1 was
eluted with a decreasing gradient of (NH4)2SO4 in the same buffer and
concentrated by ultraﬁltration (Amicon Ultra-50 K).
2.4. Enzyme kinetics
Steady-state kinetic studies of the puriﬁed refolded proteins were
carried out at 37 °C ﬂuorimetrically (Hitachi F-4500, excitation 340 nm,
emission 450 nm, 10 nm slits, lamp power 700 W). The reaction
mixtures contained 100 mM KCl and 5 mM DTT in 100 mM Tris–HCl
buffer, pH 8.0with varying amounts of IMP and NAD+ in a total volumeof 1 ml. NAD+ concentrations ranged from 10 to 200 μM and IMP
concentrations from 5 to 80 μM.
3. Results
3.1. Protein over-expression and initial refolding from solubilised
inclusion bodies
Genes encoding normal human IMPDH1 and the R224P and D226N
mutants were highly over-expressed in E. coli strain BL21(DE3) cells,
but almost exclusively in inclusion bodies (Fig. 1). After washing,
which removedmuch of the contaminating protein (Fig. 1 Lane 3), the
inclusion bodies were solubilised in 8 M guanidinium hydrochloride
(see Section 2.3). In preliminary experiments (results not shown),
samples were rapidly diluted into Tris buffer at pH 8 and at several
temperatures, and emergence of activity was monitored by spectro-
photometric assay. Highest activity, achieved within 30 min in all
cases, was obtained at 4 °C, in contrast with very low recovery at
37 °C. In seeking optimal refolding conditions, various additives were
assessed, including NAD+, IMP, DTT and arginine. IMP had little or no
effect and was ultimately omitted. Arginine, commonly used to
counteract aggregation, was beneﬁcial at room temperature but only
marginally so at 4 °C. Under otherwise optimised conditions (4 °C,
400 mM arginine, 200 μM NAD+, 10 mM DTT), the ﬁnal activity was
also highly dependent on protein concentration, with an 80-fold
increase in relative yield of active enzyme between 25 μg/ml and
400 μg/ml (Table 1a).
Table 2
Steady-state kinetic parameters of refolded human IMPDH1 WT, R224P and D226N.
Speciﬁc activity
(IU/mg)
ϕo(s) ϕIMP(μMs) ϕNAD(μMs) ϕIMPNAD
(μM2s)
kcat
(s−1)
KmIMP
(μM)
KmNAD
(μM)
WT 0.79±0.05 1.05±0.09 11.8±0.9 13.7±1.0 383±17 0.95±0.08 11.2±0.4 13.1±0.6
R224P 0.72±0.06 0.96±0.04 14.1±0.8 16.4±0.6 600±47 1.04±0.04 15.1±0.6 17.1±0.8
D226N 0.69±0.04 1.12±0.04 15.5±0.9 17.8±0.7 591±28 0.89±0.04 14.4±0.9 16.1±0.9
Column 2 gives the activities in a standard assay. Columns 3–6 give the four constants of the reciprocal initial-rate equation from a full Dalziel analysis of the initial-rate kinetics, from
which kcat (Column 7) may be derived as 1/ϕo, KmIMP (Column 8) as ϕIMP/ϕo, and KmNAD (Column 9) as ϕNAD/ϕo.
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After refolding under optimised conditions described earlier, the
normal andmutant proteinswere puriﬁed by hydrophobic interaction
chromatography as described in Section 2.3. A smooth peak (data not
shown) early in the gradient elution contained all the recovered
IMPDH1 activity. Very small peaks of absorbance at 280 nmwere seen
further into the gradient, and somewhat larger peaks eluted in a ﬁnal
water wash. A substantial amount of presumably still denatured
protein was removed by washing the columnwith sodium hydroxide.
The active fractions from the column were highly puriﬁed (Fig. 1) and
were used for detailed kinetic studies (Table 2), conﬁrming the
previous result for solubly expressed protein [5] that the mutations
caused only minor changes in speciﬁc activity and kinetic constants.
This is in keeping with the location of these mutations in the so-called
CBS domain, remote from the enzyme's catalytic machinery. The
speciﬁc activity of the refolded wild-type enzyme, at 0.79 IU/mg was,
however, somewhat lower that the ﬁgure reported earlier for the
solubly expressed protein [5].
3.3. Detailed folding studies on puriﬁed IMPDH1 proteins
With pure, soluble samples of each protein now available, the
refolding experiments were repeated. Each protein was denatured in
8 M guanidinium hydrochloride at a ﬁnal protein concentration of
1.5 mg/ml and was then diluted into refolding buffer containing
10 mMDTT and 200 μMNAD+. Once again protein concentration was
explored as a variable (Table 1b), and with the pure proteins a 10-fold
dilution to 0.15 mg/ml was optimal and was used for the remaining
experiments.
Refolding yields were assessed not only for the three pure proteins
but also for 1:1 mixtures of the normal enzyme with each of the
mutants. These experiments were carried out with and without added
arginine and at 4 °C, 25 °C and37 °C. The calculated percentage recovery
yield (Table 3) was based on regain of enzyme activity judged against
activity before denaturation. At 4 °C the recovery was remarkably high
and reasonably reproducible (80–90%) for all three proteins, even
without arginine, and, although the normal enzyme in all cases gave a
higher refolding yield than the mutants, the differences were too small
to allow any meaningful conclusions to be drawn regarding theTable 3
Refolding of pure IMPDH1 proteins and 1:1 mixtures in the absence and presence of L-Arg. T
derived from two independent experiments.
WT R224P D226N
+Arg −Arg +Arg −Arg +Arg
Speciﬁc activity
after refolding
at 4 °C (IU/mg)
0.73±0.03
(93%)
0.70±0.04
(89%)
0.64±0.03
(88%)
0.59±0.04
(81%)
0.56±0.
(82%)
Speciﬁc activity
after refolding
at 25 °C (IU/mg)
0.48±0.03
(61%)
0.18±0.04
(23%)
0.35±0.03
(48%)
0.030±0.004
(4.1%)
0.30±0.
(43%)
Speciﬁc activity
after refolding
at 37 °C (IU/mg)
0.19±0.04
(25%)
0 (0%) 0.086±0.025
(12%)
0 (0%) 0.054±0
(8%)mixtures. At 25 °C, however, clearer differences emerged between
normal and mutant enzymes. In the presence of arginine to minimise
aggregation, activity regain was 61% for the normal enzyme but only
48% and 43% respectively for R224P and D226N. Without arginine the
differences were much more marked, 23%, 4.3% and 3.2%. These
differences ﬁrst of all bear out the original assertion of Aherne et al.
[5] that in the clinical mutants the ability of the protein to fold correctly
is impaired, in the present case without any complicating issues of His
tagging. Also, however, they provide a basis for examining any effects of
oneprotein on the other. In themixtures, assuming similar folding rates,
there will be a random assortment of folding monomers, making
possible, in theory, a binomial distribution of subunits among the
various possible combinations, 4:0, 3:1, 2:2, 1:3 and 0:4. In the case of
the normal/R224P mixture, if folding of each type of subunit is entirely
independent of the presence of the other type, the ﬁnal recovery should
be an arithmetic average, 0.5×(23+4.3)%=13.7%. In fact, the recovery
was 6.4%, fairly close to the ﬁgure for the mutant by itself. Bearing in
mind also that therewill be a small proportion of tetramerswith all four
subunits normal, this suggests that any tetramer molecule containing
one or more mutant IMPDH1 subunits behaves like the mutant.
Similarly, for the D226N mutant the predicted average is 13.1% but
the actual ﬁgure achievedwas 4.9%,much closer to the ﬁgure of 3.1% for
the mutant.
At 37 °C, the calculation can only be carried out for refolding in the
presence of arginine, because at this physiological temperature none
of the proteins gave back any activity without the additive. With
arginine the ﬁgures were 25%, 12% and 8%, so that averages for the two
mixtures would be 18.5% and 16.5%. The actual ﬁgures were 14% and
10%, once again much closer to the ﬁgures for the mutants than to the
averages.
3.4. CD studies of the soluble proteins
The far u.v. CD spectra of the three proteins were compared and
revealed a striking difference between the spectrum for D226N and
those of the other two (Fig. 2) with a complete absence of the feature
at 209 nm, suggesting greater disorder in the CBS domain which could
only be conﬁrmed by further crystallographic studies. CD was also
used to evaluate stability of secondary structure, by monitoring the
signal at 222 nm as the temperature was raised at 2 °C/min from 25 tohe ﬁnal protein concentration in the refolding mixtures was 150 μg/ml. These data were
WT/R224P WT/D226N
−Arg +Arg −Arg +Arg −Arg
04 0.50±0.02
(73%)
0.69±0.04
(91%)
0.63±0.04
(84%)
0.64±0.03
(86%)
0.58±0.03
(79%)
04 0.0224±0.006
(3.2%)
0.39±0.03
(52%)
0.048±0.013
(6.4%)
0.36±0.03
(48%)
0.036±0.016
(4.9%)
.013 0 (0%) 0.11±0.04
(14%)
0 (0%) 0.075±0.014
(10%)
0 (0%)
Fig. 2. CD Spectrum for IMPDH1 and RP10 mutants. The far u.v. spectrum for normal
IMPDH1 (WT) is shown as a solid line, that for clinical mutant R224P as a dashed line
and that for clinical mutant D226N as a dotted line.
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midpoint of the transition was at 65.6 °C. R224P was somewhat less
stable, with a midpoint temperature of 62.9 °C. Again, however,
D226N stood out as markedly less stable, with a melting temperature
of 42.2 °C.
4. Discussion
This, admittedly a model study under artiﬁcial conditions,
nevertheless clearly shows that these clinical mutant proteins are
not only impaired in their own folding but are also both able, by their
presence, to impede correct assembly of the normal enzyme into
soluble active tetramers. This feature, common to both mutants,
provides a satisfying explanation for negative dominance that may
have relevance to other proteins in which the symmetry of quaternary
structure provides an opportunity for faulty subunits to subvert
proper folding and function among their neighbours. Nevertheless
there is a striking difference between the physical effects of the25 35 45 55 65 75 85
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Fig. 3. Melting curves for IMPDH1 and RP10 mutants. The three curves show the
changing CD signal at 222 nm as temperature is increased. The curve for normal
IMPDH1 (WT) is shown in red, that for clinical mutant R224P in olive and that for
clinical mutant D226N in green.mutation in the two cases. In D226N the structure, even after folding
to an active state, is markedly unstable. The reasons for this
remarkable effect are not clear but may be revealed by molecular
modelling. In R224P the enzyme, once folded, is only marginally
destabilised, and it seems that this mutation must exercise its
negative dominance in the ﬁnal stages of acquisition of a fully native
conformation by the folded oligomer. In considering the fact that,
despite the marked differences in folding and stability, the speciﬁc
activities of the proteins are similar it must be borne in mind a) that
the mutations are not in the part of the protein directly involved in
catalysis but rather in the CBS domain; b) that the activity comparison
is made only on the fully and successfully folded proteins and thus
will not reﬂect the ease or difﬁculty with which that state was
reached.
It appears likely, in the light of these results, that aggregation of the
misfolded proteins is ultimately responsible for the clinical symptoms
caused by these mutations. Nevertheless this conclusion must remain
provisional in view of a recent study [12] which has shown that the
IMPDH1 gene is expressed in different splice variants in different
tissues, and speciﬁcally that the predominant form in the retina is
modiﬁed relative to the formof IMPDH1 used in the present study. The
authors of that paper suggest that it is this tissue-speciﬁc expression
pattern that accounts also for the retina-speciﬁc manifestation of the
genetic disease in RP10. It will now need to be tested whether the
effects described here persist in the modiﬁed retinal form of the
protein. It should be emphasised, however, that the disease-causing
mutations are in the so-called CBS domain of the protein. The sequence
alterations in the splice variants are elsewhere in the structure and
there is no reason, therefore, to assume that theseminor variationswill
affect or abolish the marked effects on stability and folding produced
by the clinical mutations and documented here. It should be noted,
moreover, that the paper in question [12] provides another piece of
information that is highly relevant to our proposal, namely that the
level of expression of IMPDH1 is much higher in retina than in other
tissues. This undoubtedly would provide a reason for a tissue-speciﬁc
clinical outcome of a tendency to protein aggregation.
Finally we should consider the rival explanation currently offered
[7,8] for the clinical effect of IMPDH1 mutations, namely that DNA
binding is impaired and that any issues of aggregation are an artefact of
His tagging. The latter point can be dismissed, since noHis taggingwas
employed in the present study in contrast to the earlier study of
Aherne et al. [5]. It is entirely unclear what essential physiological
beneﬁt derives from the enzyme's ability to bindDNA,whichmay itself
be an experimental artefact. There is also no current explanation via
this hypothesis of the basis of negative dominance. Any explanation
would presumably have to invoke haploinsufﬁciency depriving the
tissue of adequate DNA binding by IMPDH1. If so, it is very difﬁcult to
see how such a hypothesis can account for the fact that total knockout
of the gene results in less visual impairment than the heterozygous
state.
Clearly a ﬁnal conclusionwill have to await further experiments, but
in the meantime it is noteworthy that our interpretation in terms of
molecular recruitment in an oligomer could well apply also to other
cases of negative dominance caused by mutations in oligomeric
enzymes and could thus have a relevance well beyond the understand-
ing of RP10.
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